Cyclacel Pharmaceuticals Inc investor relations material

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing medicines for the treatment of cancer and other proliferative diseases. Cyclacel Pharmaceuticals, Inc., is developing fadraciclib, a cyclin dependent kinase Inhibitors (CDK) program that has completed Phase 2b clinical trials for the treatment of solid tumors. The Company's development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease as well as its Phase 1/2 IST for the treatment of advanced rheumatoid arthritis.